EAN 2021 | Tools for the diagnosis of Alzheimer’s disease

Wiesje van der Flier • 8 Jun 2021

EAN 2021

Wiesje van der Flier, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses the tools available for the diagnosis of Alzheimer’s disease. These range from questionnaires for psychological assessment to lab tests, including magnetic resonance imaging (MRI), computed tomography (CT), amyloid Positron Emission Tomography (PET) and tau PET scans. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, Stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape). WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in an advisory board of Biogen MA Inc. WF is associate editor at Alzheimer’s, Research & Therapy. All funding is paid to her institution.